Lead Product(s) : Selatogrel
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Viatris
Deal Size : Undisclosed
Deal Type : Collaboration
Idorsia and Viatris Close Global Research Collaboration Transaction
Details : The collaboration focuses on the clinical development & commercialization of ACT-246475 (selatogrel), a reversible, highly selective P2Y12 inhibitor for treating Acute Myocardial Infarction.
Product Name : ACT-246475
Product Type : Other Small Molecule
Upfront Cash : $350.0 million
March 18, 2024
Lead Product(s) : Selatogrel
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Viatris
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Selatogrel
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Viatris
Deal Size : Undisclosed
Deal Type : Collaboration
Idorsia and Viatris Enter Into a Significant Global Research and Development Collaboration
Details : The collaboration focuses on the clinical development and commercialization of ACT-246475 (selatogrel), a fast-acting, selective P2Y12 inhibitor for treating Acute Myocardial Infarction.
Product Name : ACT-246475
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
February 27, 2024
Lead Product(s) : Selatogrel
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Viatris
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Aprocitentan
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Janssen Biotech
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ACT-132577 (aprocitentan) is a dual endothelin receptor antagonist, which potently inhibits the binding of ET-1 to ETA and ETB receptors. It has a mechanism of action that is ideally suited for the pathophysiology of resistant hypertension.
Product Name : Tryvio
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 31, 2023
Lead Product(s) : Aprocitentan
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Janssen Biotech
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Aprocitentan
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ACT-132577 (aprocitentan), is an investigational, novel, oral, dual endothelin receptor antagonist (ERA), which potently inhibits the binding of ET-1 to ETA and ETB receptors.
Product Name : Tryvio
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 20, 2022
Lead Product(s) : Aprocitentan
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pelacarsen
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Ionis Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : TQJ230 (pelacarsen) is a potentially first-in-class treatment specifically targeting elevated lipoprotein(a) (Lp(a)), an independent, inherited and causal risk factor for cardiovascular disease.
Product Name : TQJ230
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
July 20, 2022
Lead Product(s) : Pelacarsen
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Ionis Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Aprocitentan
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ACT-132577 (aprocitentan) reduces blood pressure compared to placebo by week 4 of treatment, the effect is maintained and confirmed over a period of 48 weeks, and is generally well tolerated with no major safety concerns.
Product Name : Tryvio
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 23, 2022
Lead Product(s) : Aprocitentan
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Inclisiran
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Alnylam Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Separate post hoc analyses of pooled Phase III ORION-9, -10 and -11 data show twice-yearly Leqvio® (inclisiran) consistently reduced LDL-C in patients with atherosclerotic cardiovascular disease with established cerebrovascular disease and polyvascular ...
Product Name : Leqvio
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
August 31, 2021
Lead Product(s) : Inclisiran
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Alnylam Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Isoquercitrin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : FDA
Deal Size : Undisclosed
Deal Type : Agreement
Quercis Announces Special Protocol Assessment Agreement with U.S. Food and Drug Administration
Details : SPA supports protocol for Phase 3 Trial of Isoquercetin to effect thromboembolic events in metastatic pancreatic cancer patients. Isoquercetin employs a novel pathway that is based on a new mechanism of action to prevent or reverse thrombus formation.
Product Name : ISQ950AN
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
April 05, 2021
Lead Product(s) : Isoquercitrin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : FDA
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Inclisiran
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Alnylam Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Pooled data analyses from Phase III ORION-9, -10 and -11 showed that inclisiran consistently reduced low-density lipoprotein cholesterol (LDL-C) by approximately 51% in both male and female adult patients and in three age categories.
Product Name : Leqvio
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
November 13, 2020
Lead Product(s) : Inclisiran
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Alnylam Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Inclisiran
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Alnylam Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Inclisiran provides effective and sustained reduction of LDL-C of up to 52%, with a safety profile similar to placebo, in patients with elevated LDL-C despite maximally tolerated lipid-lowering therapy.
Product Name : Leqvio
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
October 16, 2020
Lead Product(s) : Inclisiran
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Alnylam Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable